Pre-Existing Interstitial Lung Abnormalities Are Independent Risk Factors for Interstitial Lung Disease during Durvalumab Treatment after Chemoradiotherapy in Patients with Locally Advanced Non-Small-Cell Lung Cancer.
Wakako DaidoTakeshi MasudaNobuki ImanoNaoko MatsumotoKosuke HamaiYasuo IwamotoYusuke TakayamaSayaka UenoMasahiko SumiiHiroyasu ShodaNobuhisa IshikawaMasahiro YamasakiYoshifumi NishimuraShigeo KawaseNaoki ShiotaYoshikazu AwayaTomoko SuzukiSoichi KitaguchiKazunori FujitakaYasushi NagataNoboru HattoriPublished in: Cancers (2022)
We showed that pre-existing ILAs are risk factors for ILD during durvalumab treatment after CRT. We should pay attention to the development of grade-two or higher ILD during durvalumab treatment in patients with ILAs.